Seattle Children's Hospital
Facts
- HQ
- Seattle
- Sectors
- Healthcare, Pediatrics, Medical Research, Hospital
- Founded
- 2016 Seattle business license
- Type
- Corporation Seattle business license
- Registered name
- Seattle Childrens Hospital Seattle business license
Jacob Colker announces Seattle startups score major wins: Stoke Space $1B raise, BrainChild Bio $116M, Nuance Labs $50M, Helion expands
A roundup by Jacob Colker highlights major Seattle-area tech and biotech funding and growth: Stoke Space raised $1B (now $2.3B) for reusable rockets, BrainChild Bio $116M for a CAR-T DIPG trial, General Robotics offers rapid robot deployment, Helion expands amid fusion commercialization with 800+ employees, and Nuance Labs raised $50M for multimodal AI.
BrainChild Bio Raises $116M Series A on Sept. 8 to Fund Phase 2 B7-H3 CAR T Trial for DIPG
BrainChild Bio raised $116 million in a Series A on Sept. 8 to fund a registrational Phase 2 trial of BCB-276, a B7-H3 CAR T therapy delivered directly into cerebrospinal fluid for DIPG, and to advance a triple-antigen glioblastoma program. The Seattle Children’s spinout aims to bypass the blood-brain barrier with intrathecal delivery after promising early survival signals.
BrainChild Bio raises $116M Series A to fund Phase 2 CAR T trial for childhood DIPG
Seattle startup BrainChild Bio raised $116 million in Series A funding to advance a CAR T cell therapy for diffuse intrinsic pontine glioma (DIPG) and to support development of additional pediatric and adult brain tumor CAR T programs. The financing will fund a pivotal ILLUMINATE Phase 2 registration-stage trial and was led by an undisclosed private family fund and foundation, with participation from Seattle Children’s and WRF Capital.
BrainChild Bio Raises $116M Series A to Fund Phase 2 ILLUMINATE Trial of BCB‑276 for DIPG
BrainChild Bio, a Seattle clinical-stage biotech led by CEO Steven Brugger, raised $116M in a Series A led by an undisclosed private family fund and foundation with participation from Seattle Children’s and WRF Capital to fund Phase 2 ILLUMINATE study of BCB‑276 for DIPG and continued development of BCB‑214 for glioblastoma.
BrainChild Bio raises $116M Series A to fund pivotal Phase II trial of B7-H3 CAR T for DIPG
BrainChild Bio closed a $116 million Series A to fund a pivotal Phase II registrational trial (ILLUMINATE, NCT07680439) of BCB-276, a B7-H3-targeted CAR T therapy for DIPG, and to advance BCB-214 toward clinical testing. The company, spun out of Seattle Children's in January 2024, reported encouraging Phase I data (median overall survival 19.8 months) and has Breakthrough Therapy and RMAT designations for BCB-276.
BrainChild Bio raises $119M Series A to fund pivotal Phase 2 of CAR T BCB-276 for deadly pediatric DIPG
BrainChild Bio raised $119 million in a Series A to advance CAR T therapies for pediatric central nervous system cancers, funding a pivotal Phase 2 trial of lead asset BCB-276 for diffuse intrinsic pontine glioma (DIPG) and preclinical work on BCB-214.
BrainChild Bio raises $116M Series A to launch pivotal registrational trial of BCB-276 CAR T therapy for pediatric DIPG
BrainChild Bio, a Seattle Children’s spinout, raised $116 million in Series A funding to support a pivotal registrational trial of BCB-276, an autologous CAR T-cell therapy targeting DIPG in children, with plans to expand into adult CNS tumors including glioblastoma.
BrainChild Bio raises $116M Series A from Seattle Children’s and WRF to fund pivotal CAR-T trial for DIPG
BrainChild Bio, spun out of Seattle Children’s Hospital, raised $116 million in a Series A led by Seattle Children’s and WRF Capital to fund a pivotal phase 2 trial of CAR-T candidate BCB-276 for diffuse intrinsic pontine glioma (DIPG) and advance a planned phase 1 glioblastoma program.
BrainChild Bio raises $116M to advance CAR-T treatments for pediatric brain cancers, including Phase 2 DIPG trial
BrainChild Bio raised $116 million to advance CAR-T cell therapies for rare pediatric brain cancers, with BCB-276 in Phase 2 for DIPG and BCB-214 nearing human testing for glioblastoma.
BrainChild Bio raises $116M Series A to fund Phase 2 CAR‑T trial for pediatric diffuse intrinsic pontine glioma
BrainChild Bio raised $116 million in Series A financing to advance CAR-T therapies into the central nervous system, funding a Phase 2 trial of its lead candidate for pediatric diffuse intrinsic pontine glioma while planning future adult indications.
Seattle Startup Mpathic Raises $15M in 2025 to Make AI Chatbots Safer Using Clinical Data
Seattle startup mpathic, founded in 2021 to enhance empathy in corporate communication, is expanding to support AI developers by using clinical expertise to reduce dangerous chatbot responses, particularly for vulnerable users. The company raised $15 million in 2025 to fuel growth and has already helped slash unsafe AI outputs by over 70%.
Seattle Startup Singletto Launches FDA-Approved Virus-Killing Masks on Amazon Following $10M Funding and DARPA Support
Seattle startup Singletto, with $10 million in funding and support from DARPA, has launched FDA-approved virus-neutralizing face masks on Amazon using its Oxafence Active Protection technology that kills 99.9% of certain viruses. The masks are the only FDA-cleared products in the U.S. that inactivate tested viruses and may have applications in healthcare and national security.
UW Students' Jaundice Detection Tool Wins $17,500 at 2024 Hollomon Health Innovation Challenge
A University of Washington student team named Luminovah won the grand prize and another award at the UW Hollomon Health Innovation Challenge for developing a non-invasive jaundice detection tool effective across all skin tones. The team is partnering with Seattle Children’s for human trials aiming for FDA approval and plans to offer rental devices to parents of affected newborns.
Ex-Marine Emery Wager Leverages Afghanistan Combat Leadership in Pacific Northwest Tech Startup
Emery Wager, a former U.S. Marine and Stanford graduate, transitioned from a career in engineering to military service, inspired by the unique leadership and ambassador role in Afghanistan. His military experience now shapes his leadership style in the Pacific Northwest tech industry.
Seattle Immunotherapy Startup Umoja Biopharma Raises $100M Series C to Advance In Vivo CAR T-Cell Cancer Therapies
Seattle-based Umoja Biopharma raised $100 million in a Series C funding round to advance its CAR T-cell immunotherapy treatments, including an in vivo cell-generating technology for cancer. The company, founded in 2019 and led by CEO Andy Scharenberg, has programs in preclinical and Phase 1 stages and previously raised $263 million.
Seattle Startup Singletto Gains FDA Approval for Virus-Killing Oxafence Surgical Masks
Seattle startup Singletto received FDA approval for its Oxafence technology, a methylene blue-treated surgical mask that kills 99.9% of certain viruses within five minutes. The masks are already in use in New Zealand and represent a significant advancement over traditional masks by actively inactivating pathogens.
Flexe Names Pirasenna Thiyagarajan CTO; Talus Bioscience Appoints Gaelle Mercenne Amid $11.2M Funding; Vouched Adds David McGrath as Sales VP
Flexe appointed Pirasenna Thiyagarajan as chief technology and product officer following CTO David Glick's departure. Talus Bioscience hired Gaelle Mercenne as head of biology after securing $11.2 million in funding, while Vouched named David McGrath as vice president of sales amid leadership changes.
Harshit Shah Named CTO of Kyruus Health; Ryan Asdourian Joins Lumen as CMO and EVP; Fred Hutch Announces 2024 Weintraub Awardees
Harshit Shah, former AWS engineering head, becomes CTO at healthcare software company Kyruus Health, while Ryan Asdourian, a longtime Microsoft manager, joins telecom firm Lumen as CMO and EVP. Additionally, Fred Hutchinson Cancer Center announced 12 recipients of the 2024 Harold M. Weintraub Graduate Award.
Seattle Startup MotherDuck Hires Former Google Leaders Frances Perry and Margaret Lawrence Rosas; Humanly Adds VP of Growth Pallavi Sinha
Seattle startup MotherDuck hired Frances Perry, a former Google engineering director, as engineering manager, and Margaret Lawrence Rosas, former Looker and Google executive, as head of customer success. Additionally, Pallavi Sinha joined Seattle startup Humanly as vice president of growth.
Seattle Children’s Launches BrainChild Bio Startup to Develop CAR T-Cell Therapies for Pediatric Brain Cancer
Seattle Children’s has spun out BrainChild Bio, a biotech startup focused on developing CAR T-cell therapies for incurable pediatric brain cancers like diffuse intrinsic pontine glioma. Led by Dr. Michael Jensen, the company will operate from the Building Cure innovation hub in downtown Seattle.
Viome raises $86.5M Series C and partners with CVS to sell $179 at-home Full Body Intelligence gut test in 200 stores
Seattle-area health tech startup Viome Life Sciences raised an $86.5 million Series C and struck a deal to sell its $179 at-home Full Body Intelligence gut microbiome test in 200 CVS stores and online. Founded by Naveen Jain, Viome analyzes stool, saliva and blood samples and counts investors including Marc Benioff and Khosla Ventures, though some scientists question clinical utility of microbiome kits.
Wavely Diagnostics Raises $1.35M to Launch Smartphone App Detecting Ear Infections via Acoustic Signals in 2023
Wavely Diagnostics, a University of Washington spinout, raised $1.35 million to develop a smartphone app that detects ear infections using acoustic signals. The app aims to enable virtual pediatric care by connecting users with physicians and is slated for public release later this year.
Pacific Northwest Life Sciences Update: Talus Bioscience Raises $9.75M, Kineta Merges with Yumanity, UW’s David Baker Launches Charm Therapeutics
Recent Pacific Northwest life sciences news includes Talus Bioscience raising $9.75 million, Kineta going public via merger with Yumanity, and UW's David Baker launching Charm Therapeutics. Key partnerships involve TwinStrand and Singular Genomics developing rare gene variant tests, and Umoja Biopharma partnering with TreeFrog Therapeutics for stem cell therapies.
Former Google engineering director Ankur Sinha named Remitly CTO; Karim Meghji to advisory role in February
Ankur Sinha, formerly a Google engineering director who oversaw Google Cloud’s commerce capabilities and previously spent 12 years at Microsoft, joined Remitly as chief technology officer. Several other Seattle-area tech and health hires and role changes are noted, including Karim Meghji shifting to an executive advisory role at Remitly at the end of February.
Seattle Startup Wavely Diagnostics Raises $2.2M to Launch App Detecting Ear Infections via Acoustic Signals
Seattle startup Wavely Diagnostics raised $2.2 million to launch a smartphone app that detects ear infections using acoustic signals, enabling virtual care and treatment. The company is led by CEO Arna Ionescu Stoll and founded by experts including a pediatric ENT physician and a computer science professor.
